Skip to contentpdufa.bio

Verekitug VENTURE (Phase 2)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Verekitug VENTURE (Phase 2) is an Upstream Bio, Inc. program in chronic obstructive pulmonary disease (COPD). Its next catalyst is a Readout in Q4 2027.

UPB catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Chronic obstructive pulmonary disease (COPD). Sponsor: Upstream Bio, Inc. (UPB). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027UPB

Specialist biotech funds holding UPB, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors5,693,589$30.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is Verekitug VENTURE (Phase 2)'s next FDA decision or readout?

The next tracked catalyst for Verekitug VENTURE (Phase 2) is a Readout in Q4 2027.

What happened at Verekitug VENTURE (Phase 2)'s most recent FDA decision?

No FDA decision for Verekitug VENTURE (Phase 2) is in our archive yet.

What is Verekitug VENTURE (Phase 2) used for?

In our records Verekitug VENTURE (Phase 2) is under review or in development for Chronic obstructive pulmonary disease (COPD).

Who makes Verekitug VENTURE (Phase 2)?

Upstream Bio, Inc. (UPB).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.